个人简介

黄茂华，副研究员，博士。2015年7月毕业于广州中医药大学制药工程专业，获学士学位；2015年9月-2021年6月在暨南大学中药学系学习，获博士学位；2021年7月-2023年6月在暨南大学中西医结合博士后科研流动站开展博士后科研工作；2023年6月进入暨南大学药学院工作，先后任绿色通道聘副高、副研究员。先后主持国家自然科学基金青年基金项目、广东省自然科学基金-面上项目和广东省区域联合基金-青年基金项目等国家和省部级项目4项；作为核心成员参与国自然重大项目、国家新药创制重大专项、国自然面上项目、广东省自然重点项目等10余项。主要围绕肿瘤耐药和转移的发生机制和干预药物发现等方面开展研究工作，已发表SCI论文30余篇，其中以第一/通讯作者(含共同)在Nat Metab、Drug Resist Updat、J Clin Invest、J Extracell Vesicles、Acta Pharm Sin B、J Immunother Cancer等SCI收录杂志发表论文10余篇。参编英文著作1部，申请中国发明专利3项。讲授了多门研究生课程，协助培养硕士和博士研究生10余名。

研究方向

中药和天然药物的抗肿瘤活性成分筛选、作用机制研究以及相关创新药物的研发

周细胞调控肿瘤耐药和转移的新机制研究和靶向药物发现  

代表性论文

1.Huang MH#, Lin YN#, Wang CR#, Deng LJ, Chen MF, Yehuda G. Assaraf, Chen Z-S*, Ye WC*, Zhang DM*. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resist Updat, 2022;64:100849. (IF: 24.3，第一作者)

2.Huang MH#, Chen MF#, Qi M, Ye GN, Pan JH, Shi CZ, Yang YL, Zhao LY, Mo XK, Zhang YR, Li Y, Zhong JC, Lu WJ, Li XB, Zhang JY, Lin JR, Luo LP, Liu TZ, Tang P. M-K, Hong A, Cao YH*, Ye WC*, Zhang DM*. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. J Extracell Vesicles, 2021;10(7):e12096. (IF: 17.337，第一作者)

3.Wang CR#, Huang MH#, Lin YN#, Zhang YM, Pan JH, Jiang C, Cheng MJ, Li SR, He WZ, Li ZQ, Tu ZC, Fan J, Zeng HH, Lin JH, Wang YJ, Yao N, Liu TZ, Qi Q, Liu XN, Zhang ZM, Chen MF*, Xia LP*, Zhang DM*, Ye WC*. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 to confer resistance to antiangiogenic therapy. Nat Metab, 2023;5(10):1765-1786. (IF: 20.8，共同第一作者)

4.Wen Q#, Huang MH#, Xie JW#, Liu RY#, Miao Q, Huang JJ, Zhang JQ, Lyu WY, Qi M, Wu CY, Qi Q, Zhang ZJ, Deng R, Wang CR, Chen Z-S*, Zhang DM*, Ye WC*, Chen MF*. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resist Updat, 2023;69:100975. (IF:24.3，共同第一作者)

5.Qi M#, Fan SR#, Huang MH#, Pan JH, Li Y, Miao Q, Lyu WY, Li XB, Deng LJ, Qiu SH, Liu TZ, Deng WQ, Chu XD, Jiang C, He WZ, Xia LP, Yang YL, Hong J, Qi Q, Yin WQ, Liu XN, Shi CZ, Chen MF*, Ye WC*, Zhang DM*. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models. J Clin Invest. 2022;132(19):e157399. (IF: 15.9，共同第一作者) 

6.Huang MH#, Liu MQ#, Huang DD#, Ma YP, Ye GN, Wen Q, Li Y, Deng LJ, Qi Q, Liu TZ, Liu XN, Chen MF*, Ye WC*, Zhang DM*. Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. Cancer Lett, 2022, 524:131-143. (IF: 9.7，第一作者)

7.Huang MH#, Qi M#, Yang HY#, Peng Z, Chen SG, Liang MC, Hu YZ*, Deng LJ*, Hu M*. Noninvasive strategies for the treatment of tiny liver cancer: integrating photothermal therapy and multimodality imaging EpCAM-guided nanoparticles. ACS Appl Mater Interfaces, 2023;15(18):21843-21853. (IF: 9.5，第一作者)

8.Ye GN#, Huang MH#, Li Y, Ouyang J, Chen MF, Wen Q, Li XB, Zeng HH, Long P, Fan ZP, Yin JQ*, Ye WC*, Zhang DM*. The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the Axl pathway. Acta Pharm Sin B, 2022;12(3):1288-1304. (IF: 14.5，共同第一作者)

9.Wang S#, Huang MH#, Chen MF#, Sun ZT#, Jiao YB, Ye GN, Pan JH, Ye WC*, Zhao JF*, Zhang DM*. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells. J Immunother Cancer, 2023;11(6):e006381. ( IF: 10.9，共同第一作者)

10.Mai WQ#, Chen MF#, Huang MH#, Zhong JC, Chen J, Liu XY, Deng J, Yang XX, Ye WC, Zhang RJ*, Zhou Q*, Zhang DM*. Targeting platelet-derived growth factor receptor β inhibits the proliferation and motility of human pterygial fibroblasts. Expert Opin Ther Targets, 2019, 23(9):805-817. (IF: 5.473，共同第一作者)

11.Lin JP#, Huang MH#, Sun ZT#, Chen L, Lei YH, Huang YQ, Qi M, Fan SR, Chen SG, Chung CW, Chan MC, Liu JS, Hu M, Chen MF, Ye WC, Chen YY*, Deng LJ*. Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT/NF-κB pathway. Life Sci, 2023;324:121715. (IF: 6.780，共同第一作者)

12.Ye GN#, Jiao YB#, Deng LJ#, Cheng MJ, Wang S, Ou-yang J, Li Y, He YX, Tu ZC, Wang Z, Song XJ, Wang CR, Qi Q, Zhang DM, Wang L*, Huang MH*, Ye WC*, Chen MF*. Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway. Int J Biol Sci, 2023;19(14):4376-4392. (IF: 9.2，共同通讯作者)